GlaxoSmithKline announced that among patients with platinum-resistant ovarian cancer, the median progression-free survival with Morez therapy reached 11.1 months. GlaxoSmithKline also announced that in ovarian cancer trials, the objective remission rate confirmed by Moretz therapy was 62%, with a median remission duration of 12.2 months.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.